Asthma biologics

Abbas, Farrukh; Georas, Steve N.; Cai, Xueya; Khurana, Sandhya

doi:10.1016/j.anai.2021.08.416

Cited by 19 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first disease, for which biological treatment targeted on the T2 endotype has been used, is asthma [15]. The main goal of biologic therapies in asthmatic patients is to reduce the number of exacerbations, oral systemic corticosteroid (OCS) use, and provide good disease control [16]. Main T2 targets are IgE with omalizumab (OMA), IL-5 with mepolizumab (MEP) and reslizumab, IL-4 with dupilumab (DUP), and IL-5 receptor Alpha with benralizumab (BEN) [17].…”

Section: Current Targetsmentioning

confidence: 99%

The new indications for biologicals in type 2 diseases: perspectives

Bagnasco

Canevari

Passalacqua

et al. 2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewTo provide a literature review of what is on the market and under study for some diseases treated with drugs targeting type 2 (T2) inflammation.Recent findingsLiterature data have shown that drugs targeting type 2 inflammation are effective in asthma and nasal polyposis, conditions for which they are on the market, and have promising expectations in the case of eosinophilic esophagitis, especially using anti-IL-5/IL-5 receptor and IL-4 receptor antibodies, while concerning eosinophilic granulomatosis with polyangitis (EGPA), mepolizumab (MEP) was approved by FDA and EMA as a drug for the treatment of this condition because of the promising results obtained in trials and in real life.SummaryThe use of these drugs is certainly an important achievement in the treatment of complex diseases such as those mentioned above, which are too often orphaned from innovative treatments and limited to the use of immunosuppressants and systemic corticosteroid for their control.

show abstract

Section: Current Targetsmentioning

confidence: 99%

The new indications for biologicals in type 2 diseases: perspectives

Bagnasco

Canevari

Passalacqua

et al. 2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Moreover, healthcare claims data cannot easily capture SA and exacerbations. Patient-reported outcomes (PROs) can be helpful in clinical decision-making, and if integrated into RCDs, they can increase the value and utility of RWD [ 44 , 45 ]; however, PROs are not routinely measured in most real-world practices.…”

Section: Rwe: Overviewmentioning

confidence: 99%

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Lee

Park

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

Recent advances in asthma research have led to the development of novel biologics that hinder the pathologic actions of key molecules in severe asthma (SA). Traditional randomised controlled studies (RCTs), the gold standard for evaluating the efficacy and safety of medical interventions with excellent internal validity, have proven the clinical benefits and favourable safety profiles of type 2-biologics in SA. However, RCTs are not always ideal because of shortcomings such as limited external validity and practical issues in the management of SA that could not be solved through strictly designed clinical trials. Thus, the applicability of their findings may be questioned for asthmatic patients because treatment adherence is frequently poor in the real world. Real-world evidence (RWE) includes a wide range of real-world data (RWD) collected from multiple sources in clinical practice, such as electronic medical records, healthcare insurance claims, and retrospective or prospective patient registries. It may help clinicians make decisions about the management of patients with SA. RWE is also gaining attention to address clinical questions not answered by traditional RCTs. Since there are various types of RWD with different possibilities and limitations, and thus it is important to decide which type of RWD could be “fit for purpose” to address a specific question. This narrative review is to discuss the challenges and opportunities of RWD for evaluating the effectiveness and clinical outcomes of biological treatments for SA.

show abstract

“…Open-label and real-world studies have provided further insight into effectiveness of these biologics and effects of switching to a second or third biologic in patients with suboptimal clinical response to an initial biologic therapy [51][52][53][54]. OSMO was a multicenter, open-label trial examining the efficacy of mepolizumab in 138 patients with asthma not optimally controlled with omalizumab [53].…”

Section: Switching Between Biologicsmentioning

confidence: 99%

“…Reslizumab therapy was effective in attenuating airway and blood eosinophilia and associated with improved asthma control. Another retrospective single-center study in 112 patients found that treatment with any biologic was associated with a 59% reduction in clinically significant exacerbations and 54% reduction in mean maintenance OCS dose [51].…”

Section: Switching Between Biologicsmentioning

confidence: 99%

Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine

Mustafa

Patrawala

Khurana

2022

Current Opinion in Pulmonary Medicine

Self Cite

View full text Add to dashboard Cite

Purpose of reviewThere are multiple FDA-approved biologics to treat poorly controlled moderate-to-severe asthma. Given the heterogeneity of asthma and the lack of head-to-head data between biologics, selecting the best biologic for a patient can be difficult. This review summarizes the key literature to date, in hopes of facilitating an evidence-based approach to selecting the most appropriate biologic for patients with asthma.Recent findingsIn addition to unique mechanisms of action, there is increasing literature on predictors of response to each biologic, such as sensitizations to aeroallergens, peripheral eosinophil count, total serum IgE, and exhaled nitric oxide. Biologics available for asthma are also being increasingly studied in comorbid conditions with asthma, and this may facilitate selecting the most appropriate biologic for a patient. In the absence of head-to-head studies, there is literature of switching between biologics whenever necessary.SummaryThe authors outline an approach to selecting a biologic based on various considerations, and hope this suggested approach facilitates selecting the biologic most suitable for each individual with poorly controlled moderate-to-severe asthma.

show abstract

Asthma biologics

Cited by 19 publications

References 29 publications

The new indications for biologicals in type 2 diseases: perspectives

The new indications for biologicals in type 2 diseases: perspectives

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine

Contact Info

Product

Resources

About